Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK127 + AK104 in advanced solid tumors
NCT05021120Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Oct 2021
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AK127 in solid tumor, sponsored by Akeso, Inc. Primary endpoints: Adverse Events at 90 days and Dose Limiting Toxicity at 6 weeks. Started Oct 2021; status: completed.
02
Drugs
AK127
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05021120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05021120.